Axsome Therapeutics, Inc. (AXSM) Form 8-K — Nov 2, 2026
Axsome Therapeutics reported Q3 2026 total net product revenue of $259.7 million, up 52% year-over-year, surpassing a $1 billion annualized run rate. AUVELITY led with $207.6 million in net sales (+53% YoY), while SUNOSI delivered $48.2 million (+47%) and SYMBRAVO $3.9 million (+88%). Net loss narrowed dramatically to $12.9 million ($0.25 per share) from $47.2 million ($0.94) a year ago, with cash of $313.9 million that the company says is sufficient to fund operations into cash flow positivity.
Key figures
- Revenue
- 259700000
- Revenue Yoy
- 52%
- Cash Position
- 313900000
- Shares Outstanding
- 52576839
- Debt face value
- $190M
- Axs12 pdufa date
- May 1, 2027
- Rd expense q3 2026
- $50.6M
- Sga expense q3 2026
- $203.1M
- Auvelity trx q3 2026
- ~302,000 (+40% YoY)
- Prior year q3 revenue
- $171.0M
- Prior year q3 net loss
- $47.2M ($(0.94)/share)
- Auvelity net sales q3 2026
- $207.6M (+53% YoY)
- Sunosi net revenue q3 2026
- $48.2M (+47% YoY)
- Symbravo net sales q3 2026
- $3.9M (+88% YoY)
- Annualized revenue run rate
- >$1 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.